Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

Panelists discuss how treatment goals for patients with lower-risk MDS are established and analyze the findings of Oliva et al’s study on the relationship between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk MDS treated with luspatercept or epoetin.

EP: 1.Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP: 2.Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP: 3.Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

Now Viewing

EP: 4.Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP: 5.First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP: 6.Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP: 7.Second-Line LR- MDS Setting: Treatment Options and Considerations

EP: 8.Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP: 9.Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP: 10.First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP: 11.Imetelstat and IMerge Trial Review

EP: 12.Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP: 13.The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

• What are your treatment goals for patients with lower-risk MDS?
• Please comment on the findings of Oliva et al with regard to the relationship between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk MDS treated with luspatercept or epoetin (EHA 2024; abstract P774).

Related Videos